# A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)

> **NCT02806648** · PHASE2 · COMPLETED · sponsor: **Grupo Espanol de Tumores Neuroendocrinos** · enrollment: 21 (actual)

## Conditions studied

- Pancreatic Neuroendocrine Cancer

## Interventions

- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT02806648
- **Lead sponsor:** Grupo Espanol de Tumores Neuroendocrinos
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2017-07
- **Final completion:** 2018-01
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2018-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02806648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02806648, "A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02806648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*